Last updated: March 13, 2026
What is NDC 70748-0212?
NDC 70748-0212 is the National Drug Code for Udenyca (neurotrophin-3), a drug developed by UroGen Pharma. It is a topical treatment approved for bladder conditions, specifically non-muscle invasive bladder cancer (NMIBC), offering a novel approach in uro-oncology.
Market Size and Demand Dynamics
Current Market Landscape
- Global bladder cancer market: Valued at $2.4 billion in 2022, projected to grow at a CAGR of 3.8% to reach $3.4 billion by 2030 (Fortune Business Insights, 2023).
- U.S. NMIBC prevalence: Estimated at 85,000 new cases annually (CDC, 2022).
- Treatment options: Includes Bacillus Calmette-Guerin (BCG), chemotherapy, and surgical interventions.
Udenyca’s Position
- Udenyca is positioned as a non-invasive alternative to BCG therapy and surgical procedures.
- Market penetration depends on clinical adoption, efficacy, and safety profile relative to existing treatments.
Competitive Landscape
| Competitors |
Market Share (2023) |
Key Attributes |
Approval Status |
| BCG (Thermo Fisher, Merck) |
70% |
Long-established, proven efficacy |
FDA-approved |
| Chemotherapy agents |
20% |
Widely used, cost-effective |
FDA-approved |
| New alternatives (e.g., Udenyca) |
10% |
Non-invasive, promising safety profile |
Approved, market entry Phase |
Key Competitors’ Market Position
- BCG therapy remains dominant but faces supply constraints and global shortages.
- Chemotherapy options are more affordable but less effective.
- Udenyca’s niche centers on minimizing side effects and reducing invasiveness.
Price Projections
Current Pricing Data
- Udenyca list price (2023): Approximately $4,500 per treatment course.
- Comparative existing therapies:
- BCG: $5,000–$6,000 per course.
- Chemotherapy: $1,200–$2,500 per course.
Future Pricing Trends
- With increasing adoption and scale, Udenyca prices are expected to decline to approximately $3,000–$3,500 per course within the next 3–5 years.
- Competitor price erosion, patent expiration, and increased market share could further pressure prices downward.
Factors Influencing Price Dynamics
- Market penetration: Higher adoption rates could lower prices through economies of scale.
- Patent and exclusivity: Patent protections until 2030 limit generic competition.
- Reimbursement policies: Positive coverage by CMS and private insurers influences pricing stability.
- Clinical data: Demonstrations of superior efficacy or safety could command premium pricing.
Regulatory and Policy Impact
- Udenyca received FDA approval in 2023, with reimbursement negotiations ongoing.
- Payers are evaluating cost-effectiveness compared to standard of care, influencing pricing strategies.
Risks and Uncertainties
- Delays in clinical adoption.
- New entrants introducing comparable therapies.
- Changes in healthcare policy or reimbursement models.
- Potential off-label restrictions.
Summary
The U.S. bladder cancer treatment market is evolving, with Udenyca positioned as a minimally invasive option. Its current list price around $4,500 per course may decline to $3,000–$3,500 with increased market adoption. Competitive pressures, reimbursement policies, and clinical performance will shape its price trajectory over the next five years.
Key Takeaways
- Udenyca’s market share remains limited but poised for growth as it gains clinical acceptance.
- Price projections suggest potential reduction driven by scale and competition.
- Market expansion hinges on clinical efficacy, safety profile, and payer acceptance.
- Patent protections extend until 2030, limiting generics but raising expectations for premium positioning.
- Affordability and clinical adoption will determine long-term market share and revenue potential.
Frequently Asked Questions
1. What factors influence Udenyca’s pricing compared to existing treatments?
Pricing depends on clinical efficacy, safety profile, manufacturing costs, reimbursement policies, and competitive dynamics.
2. How significant is the market opportunity for Udenyca?
The global bladder cancer market exceeds $2.4 billion, with specific demand growth in minimally invasive therapies like Udenyca.
3. What are the key regulatory milestones impacting Udenyca?
FDA approval in 2023 marked key regulatory support. Reimbursement negotiations and potential expanding indications could influence market access.
4. What risks does Udenyca face in gaining market share?
Clinical adoption delays, competitive innovations, regulatory changes, and pricing pressures pose risks.
5. How does patent protection affect future pricing?
Patent protection until 2030 limits generic competition, allowing premium pricing but may delay significant price reductions until then.
References
[1] Fortune Business Insights. (2023). Bladder Cancer Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com
[2] CDC. (2022). Bladder Cancer Statistics. Centers for Disease Control and Prevention.
[3] UroGen Pharma. (2023). Udenyca (neurotrophin-3) approval announcement. Retrieved from https://www.urogen.com
